Astrazeneca (AZN) EBITDA (2009 - 2026)

Astrazeneca's EBITDA history runs 18 years deep, the most recent figure standing at $2.7 billion for Q1 2026.

• In Q1 2026, EBITDA fell 32.6% year-over-year to $2.7 billion; the TTM figure through Mar 2026 stood at $11.6 billion (up 36.71% YoY), while the FY2025 annual figure was $12.9 billion, up 107.27% from the prior year.
• EBITDA was $2.7 billion for Q1 2026 at Astrazeneca, down from $2.8 billion in the prior quarter.
• In the past five years, EBITDA ranged from a high of $4.0 billion in Q1 2025 to a low of -$111.0 million in Q4 2024.
• Historically, EBITDA has averaged $1.9 billion across 5 years, with a median of $1.8 billion in 2023.
• The sharpest annual moves came in 2024 and 2025: EBITDA tumbled 106.24% in 2024, then jumped 2603.6% in 2025.
• A 5-year view of EBITDA shows it stood at $1.7 billion in 2022, then rose by 3.91% to $1.8 billion in 2023, then sank by 106.24% to -$111.0 million in 2024, then surged by 2603.6% to $2.8 billion in 2025, then retreated by 2.41% to $2.7 billion in 2026.
• The last three EBITDA figures came in at $2.7 billion (Q1 2026), $2.8 billion (Q4 2025), and $2.6 billion (Q3 2025), per Business Quant data.